Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus
BZ Group
Dark Mysteries — Unsolved Mysteries. Forgotten Secrets. Unanswered Questions.
Darkest Mysteries Online
Eye On The Sky
Vermont Public
wifiCFI
wifiCFI
二奇物语
剁椒，老猫
Seventy3
任雨山
Accès au Marché Mondial des Dispositifs Médicaux
Pure Global
Глобальный доступ на рынок медицинских изделий
Pure Global
चिकित्सा उपकरण वैश्विक बाजार पहुंच
Pure Global
Tıbbi Cihazlar Küresel Pazar Erişimi
Pure Global
Akses Pasar Global Alat Kesehatan
Pure Global
Travelers In The Night
Albert D. Grauer
Icebergs y Misterios
Icebergs y Misterios
Astronomie : Fragments d'Univers
Astronomie : Fragments d'Univers
Yoga Therapy Hour with Amy Wheeler
Amy Wheeler
Science Tech Brief By HackerNoon
HackerNoon
Futurism Tech Brief By HackerNoon
HackerNoon
Paranormal UK Radio Network
Paranormal UK Radio Network
Typical Skeptic Podcast
Robert Kalil
Interplace
Brad Weed
Georgia Today
Georgia Public Broadcasting
Western Slope Skies
艾灸养生108招 |病来了，不用怕
冯名雨艾灸
UnHerd with Freddie Sayers
UnHerd
An Analog Brain In A Digital Age | With Marco Ciappelli
Marco Ciappelli
Living Planet
DW
InfectoCast
InfectoCast
Ciência para não cientistas
Jorge Guerra Pires, PhD
The Secret Teachings
Ryan Gable
Alexis Knight l Facts First. Clarity Always.
Alexis Knight | Facts First. Clarity Always.
Water Colors Aquarium Gallery
Water Colors Aquarium Gallery
Vogel der Woche - bird of the week
rudiguricht
Conspicuous Cognition Podcast
Dan Williams
Blue Dot
Dave Schlom, Matt Fidler
Reflections on Interpretation: Talking Story with Guides and Interpreters
timfmerriman
Matt From Nomad’s
Matt Crabtree
Átomos y Bits
Agencia EFE
Science
BZ Group
Federal court blocks Colorado's 70% price cap on Enbrel — ruling could shut down state drug pricing laws nationwide. Plus: Casgevy label expansion to age 2 for SCD/TDT sends CRISPR Therapeutics surging 8%. Moderna mFLUSI...
Roche's divarasib beats both KRAS G12C rivals on PFS and OS in head-to-head Phase 3, hitting survival significance at interim. AstraZeneca returns to CSPC in a $1.7B siRNA kidney disease deal; Abivax surges on $920M rais...
FDA approves Orca Bio's Tregzi — the first precision-engineered cell therapy for allogeneic transplant, sparking IPO speculation. Plus BridgeBio secures $1B from Sixth Street and KKR at a 100%+ conversion premium, Ipsen'...
NEJM retracts Amgen's ADVOCATE study after FDA findsendpoint data for 9 patients re-evaluated post-unblinding. Plus: Ionis faces the Tryngolza sNDA PDUFA in severe hypertriglyceridemia, AbbVie's Epkinly delivers chemo-fr...
Lilly at $1,230 — trading above analyst consensus — as orforglipron faces its FDA verdict tomorrow. Three label items to watch beyond the headline, plus healthcare's dramatic sub-sector bifurcation: drug makers up 25% YT...
FDA breaks Amgen's Tepezza monopoly with Viridian's Lumvoa approval in thyroid eye disease. Plus Merck KGaA's $11.3B Bio-Techne acquisition, Biogen gutting the Apellis pipeline post-$5.6B deal, CHMP moves to revoke Tavne...
FDA approves Ionis Tryngolza as first treatment to reduce pancreatitis risk in severe hypertriglyceridemia — a potential blockbuster expansion. Merck KGaA acquires Bio-Techne for $11.3B in largest deal in a decade. SCOTU...
Gilead's Trodelvy wins front-line triple-negative breast cancer approval — and the stock barely moves. Lilly expands its Abbisko partnership to $1.9B, Novartis pays $105M upfront to Antares for undruggable cancer targets...
Pfizer's sigvotatug vedotin disappoints in Phase 3 NSCLC — another blow to the $43B Seagen deal. Plus CMS settles with Incyte on Opzelura classification, Sangamo Therapeutics closes after 30 years, and Moderna's flu vacc...
AbbVie bets $10.9B on Apogee Therapeutics to challenge Dupixent — its biggest deal since Allergan. Plus: the first CAR-T approved for a solid tumor clears in China, Merck's $10.8B Prometheus IBD bet pays off with a Phase...
US government opens formal probe into Germany's drug pricing reforms, escalating transatlantic pharma trade tensions. Kardigan IPO raises $400M and pops 31%. Moderna flu vaccine gets unanimous FDA advisory panel support ...
Moderna's mRNA flu vaccine gets unanimous FDA panel backing — PDUFA August 5. NovoCure's TRIDENT trial misses overall survival in glioblastoma; stock drops ~18%. Biogen acquires immunology startup RayThera for up to $1B;...
UniQure surges 70% as FDA reverses course on Huntington's gene therapy AMT-130 filing path. Jazz and AbCellera strike $4.1B T cell engager deal for GI cancers. Novo Nordisk faces $25M ransom demand after hackers claim dr...
BridgeBio's BBP-418 sweeps Phase 3 in limb-girdle muscular dystrophy — stock up 15%, no approved competition. FDA briefing docs challenge Moderna mFlusiva efficacy ahead of Thursday's VRBPAC vote. Plus Lilly acquires non...
CMS proposes closing Medicare negotiation loophole threatening Keytruda and Opdivo subcutaneous strategies — billions at stake. Plus Takeda's zasocitinib tops Sotyktu, Novartis validates $12B Avidity deal, Elicio's KRAS ...
The Pharma Closeout's comprehensive recap of EHA 2026(Stockholm, June 11-14). HEADLINE: J&J's MonumenTAL-3 (talquetamab +daratumumab) in earlier-line R/R myeloma — PFS HR 0.28/0.33, complete-response 71% vs 34.5%, NEJM-p...
FDA approves Merck's Welireg-Keytruda combo for adjuvant kidney cancer — 28% risk reduction vs. active Keytruda monotherapy in LITESPARK-022. Jazz's Zepzelca misses OS endpoint in Phase 3 LAGOON, Incyte acquires Vega The...
Zasocitinib hits 35% complete skin clearance at week 16,topping Sotyktu by more than 2.5x in Takeda's head-to-head Phase 3. Plus: Novartis validates its $12B Avidity AOC platform in FSHD, Summit withdraws $500M offering,...
Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for riliprubart in CIDP. TG Therapeutics surges on Briumvi myasthenia gravis...
The Pharma Closeout's full recap of the American Diabetes Association's 86th Scientific Sessions (New Orleans,June 5-8, 2026) - the meeting that ended the A1C-only era and reset what obesity medicine can do. Hosts Alex M...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.